A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To assess pharmacokinetic properties of rCD4 in humans. To obtain a preliminary indication of the antiviral effects of rCD4 in patients with AIDS and AIDS related complex (ARC).

Key facts

Study ID: NCT00002004
Run by: Genentech, Inc.
Last updated by the study team: 2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have:
HIV-1 seropositivity.
Diagnosis of AIDS or AIDS related complex (ARC).
Failure to tolerate or respond to zidovudine (AZT) or decided to decline AZT therapy.
The ability to sign a written informed consent form prior to treatment.
A willingness to abstain from all other experimental therapy for HIV infection during the entire study period.
A life expectancy of at least 3 months.

You may not qualify if…

Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Serious active opportunistic infections.
Malignancies other than Kaposi's sarcoma.
Concurrent Medication:
Excluded:
Zidovudine (AZT).
Corticosteroids.
Nonsteroidal anti-inflammatory agents (NSAI).
Other experimental therapy.
Patients with the following are excluded:
Serious active opportunistic infections.
Malignancies other than Kaposi's sarcoma.
Prior Medication:
Excluded within 3 weeks of study entry:
Zidovudine (AZT).
Chemotherapy.
Immunomodulators.
Other experimental therapy.

Where it is running

Genentech Inc — South San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.